V-DOS 47

Drug Profile

V-DOS 47

Alternative Names: V-DOS-47

Latest Information Update: 01 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Helix BioPharma
  • Developer Helix BioPharma; Helix Polska; National Research Council Canada
  • Class Drug conjugates; Immunoconjugates; Ureases
  • Mechanism of Action Vascular endothelial growth factor receptor-2 modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Breast cancer
  • Research Cancer

Most Recent Events

  • 01 Sep 2017 Helix Biopharma has patent protection for DOS47 technology (Helix BioPharma pipeline, August 2017)
  • 16 Mar 2017 Preclinical trials in Breast cancer in Poland (unspecified route)
  • 19 Jul 2016 Early research in Cancer in Canada (unspecified route) before July 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top